Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combo for Unresectable Oral Cavity SCC
NCT06081582Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in oral cavity squamous cell carcinoma (OCSCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Major Pathological Response at 1 year. Status: unknown.
02
Drugs
toripalimab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT06081582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081582.